DowdenH, MunroJ. Trends in clinical success rates and therapeutic focus. Nat. Rev. Drug Discov. 2019; 18(7): 495–496. DOI: 10.1038/d41573-019-00074-z.
2.
MorganP, BrownD, LennardS, et al.Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat. Rev. Drug Discov. 2018; 17(3): 167–181. DOI: 10.1038/nrd.2017.244.
3.
MartufiM, GoodRB, RapiteanuR, et al.Single-Step, High-Efficiency CRISPR-Cas9 Genome Editing in Primary Human Disease-Derived Fibroblasts. CRISPR J., 2019; 2(1): 31–40. DOI: 10.1089/crispr.2018.0047.
4.
SchoberK, MüllerTR, GökmenF, et al.Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function. Nat. Biomed. Eng. 2019; 3(12): 974–984. DOI: 10.1038/s41551-019-0409-0.
